14 results about "M2 phenotype" patented technology

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

The application provides an amphiphilic functionalized D-form-alanine and a preparation method and application thereof, and a self-targeting carbon monoxide nanogenerator and a preparation method and application thereof, and belongs to the technical field of antibacterial materials. The application provides an amphiphilic functionalized D-form-alanine. The self-targeting carbon monoxide nanogenerator prepared by using the amphiphilic functionalized D-form-alanine changes the permeability of the outer membrane of the cell wall of gram-negative bacteria, is metabolically utilized by bacteria in a specific manner, generates CO under the action of light to kill bacteria, removes biofilms that are not easy to touch and are hidden in deep periodontal pockets, simultaneously relieves inflammation by inducing macrophages to polarize from an M1 phenotype to an M2 phenotype, further promotes alveolar bone regeneration, and avoids damage to normal tissues.

The present application relates to a DNA drug, a gene targeting delivery system and its application in the treatment of lower extremity peripheral arterial disease. Specifically, the present application relates to a microcrystalline nanocarbon targeted drug delivery system and a plasmid containing human interleukin-4 gene loaded thereon. The delivery system comprises a matrix microcrystalline nanocarbon, and folate, polyethyleneimine and polyethylene glycol modified on the surface thereof. The matrix microcrystalline nanocarbon has a size of 5-20 nanometers, a crystallinity of >80%, a rich mesoporous structure, a high specific surface area and good biocompatibility. The present application also provides a preparation method of the system, which comprises the steps of synthesizing a matrix by pulse modulation radio frequency plasma enhanced chemical vapor deposition, surface functionalization modification and plasmid loading. After injection into the lower extremity muscle, the system can actively target the macrophages in the ischemic site, realize long-term expression of the IL-4 gene at the lesion site. It can effectively promote stable, mature functional angiogenesis by inducing macrophages to polarize to the repair M2 phenotype and regulating the OSM / GSNOR / ENG signal axis, thereby improving limb ischemia. The present application has important application value in the field of gene therapy for ischemic diseases, especially peripheral arterial disease and severe limb ischemia.

This invention discloses a method, system, and apparatus for computer-aided drug screening based on temozolomide and ADAMTS1. This application is the first to discover that ADAMTS1 is significantly enriched in recurrent gliomas following temozolomide exposure; temozolomide strongly induces a stable senescence program, leading to excessive secretion of ADAMTS1. This senescence-induced protease coordinates significant changes in extracellular matrix composition. The remodeled microenvironment acts as a mechanobiochemical signaling agent, recruiting and polarizing host-derived myeloid cells to transform into the immunosuppressive M2 phenotype, thereby conferring chemotherapy resistance to residual glioma cells through paracrine signaling. This application reveals that the "senescence-ADAMTS1-ECM-M2" axis is a key non-cellular autonomous mechanism of temozolomide resistance. Targeting ADAMTS1-mediated matrix reprogramming can eliminate the immunosuppressive niche in gliomas and overcome chemotherapy resistance, showing broad application prospects.

This invention belongs to the field of biotechnology, specifically disclosing a cRGD peptide-functionalized extracellular vesicle derived from mesenchymal stem cells, its preparation method, and its applications. The extracellular vesicle surface is anchored to the cRGD peptide via membrane fusion technology, enabling active targeting and activation of microglia. The preparation method includes isolating and culturing mesenchymal stem cells, purifying natural vesicles by differential ultracentrifugation, and then co-incubating with DSPE-PEG-cRGD for membrane insertion modification. In vitro and in vivo experiments show that the vesicles can be efficiently taken up by activated microglia, delivering endogenous miRNAs, inhibiting the NF-κB pathway, and promoting the transformation of microglia from the M1 to the M2 phenotype. In a retinal ischemia / reperfusion injury model, intravitreal injection of the vesicles reduces retinal ganglion cell apoptosis, protects retinal structure and optic nerve integrity, and restores electroretinogram function. This invention can be used to prepare drugs to alleviate neuroinflammation caused by acute glaucoma.

The application discloses a preparation method of a 3D printing cerium hydroxyapatite bone repair scaffold material, and comprises the following steps: adding phenyl (2, 4, 6-trimethylbenzoyl) lithium phosphate salt powder into manganese-chelated deferoxamine grafted methylacryl gelatin, stirring, adding cerium hydroxyapatite nanowires which are surface-modified by citric acid, and stirring to obtain 3D printing slurry; and the 3D printing slurry is extruded by a 3D printer while being cross-linked by 365nm ultraviolet irradiation to obtain the 3D printing cerium hydroxyapatite bone repair scaffold material; the material has good biocompatibility, can promote vascularization and immune regulation, and can effectively regulate M2 phenotype differentiation of RAW264.7, so that more BMP-2 and PDGF-bb growth factors are secreted, osteogenesis differentiation and angiogenesis are promoted, and bone defect repair is promoted from the perspective of immune regulation.

This invention discloses a network-like porous poly(3,4-hydroxybutyrate) microsphere, its preparation method, and its applications, belonging to the field of biomedical materials technology. The microspheres exhibit a villous network structure with a continuous, irregular "ridge-valley" topology on their surface. The network-like porous poly(3,4-hydroxybutyrate) microspheres provided by this invention maintain good structural integrity even after 6 months of in vivo implantation, significantly increase ATP levels in fibroblasts under glucose-free conditions, and inhibit cell senescence. They also induce macrophages to transform from a pro-inflammatory M1 phenotype to a pro-repair M2 phenotype, avoiding the excessive inflammatory response commonly seen in PLLA-type microspheres, and demonstrate superior collagen regeneration promotion compared to PLLA-type microspheres. Furthermore, they facilitate cell adhesion and proliferation.

The present invention provides a method for producing cells polarized to the M2 phenotype, said method comprising culturing mononuclear phagocyte system cells in a suitable medium comprising lactic acid or a lactic acid derivative, and subjecting said cells to a period of hypoxia followed by a period of reoxygenation. The present invention also provides compositions comprising cells obtained with the method as defined herein and uses thereof.

The application relates to the field of biological medicine, and particularly relates to application of a curcumin compound in preparation of a medicine for treating periodontitis, and comprises the following steps: a mono-carbonyl curcumin analogue with a structure shown in formula (I) is used for preparing the medicine for treating periodontitis, and the compound is obtained by replacing a beta-diketone group of natural curcumin with a mono-carbonyl connecting group. The compound provided by the application has a chemical stability which is significantly better than that of natural curcumin, and solves the problems of easy degradation and low bioavailability; meanwhile, the compound has excellent broad-spectrum anti-periodontal pathogenic bacteria activity and immune regulation capacity, can significantly promote M2 phenotype polarization of macrophages and inhibit generation of key pro-inflammatory cytokines, realizes double effects of antibiosis and immune regulation, and provides a new, efficient and low-toxicity auxiliary treatment medicine for periodontitis.

The application belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of a polyketide compound from a fungus of the genus Arenarius. The polyketide compound can dose-dependently reduce the NO generation level in cells, significantly inhibit M1 phenotype polarization and promote the conversion of the M1 phenotype to the M2 phenotype, significantly down-regulate the expression of key inflammatory-related proteins (including IL-1beta, IL-6, TNF-alpha and COX-2) in cells, and inhibit the generation of NLRP3 inflammasome and caspase-1, revealing the potential anti-AD activity and indicating that the polyketide compound has a good application prospect in the preparation of anti-neuroinflammatory drugs. In addition, the polyketide compound can be prepared from a marine microorganism Arenarius fungus, and the preparation method is simple and the source is rich.

Aspects of the present disclosure include methods for modulating macrophage activity. Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

This invention discloses a reactive oxygen species (ROS) responsive glycyrrhizic acid anti-inflammatory hydrogel and its application in the preparation of drugs for treating compressive neuropathic pain. Belonging to the field of biomedical materials technology, the hydrogel uses glycyrrhizic acid and 1,4-phenylboronic acid as raw materials. It is heated in an alkaline environment until a homogeneous mixed solution is formed, and then naturally cooled to room temperature to obtain the ROS responsive glycyrrhizic acid anti-inflammatory hydrogel. This hydrogel possesses good injectability, self-healing properties, biocompatibility, and biodegradability. It can specifically cleave borate ester bonds in the highly reactive oxygen species pathological microenvironment of diabetic patients with lumbar disc herniation, releasing glycyrrhizic acid on demand. By targeting and regulating the PI3K-AKT signaling pathway, it promotes the polarization of macrophages from a pro-inflammatory M1 phenotype to a reparative M2 phenotype, significantly inhibiting the inflammatory response of the dorsal root ganglion and the dorsal horn of the spinal cord, effectively relieving compressive neuropathic pain in the dorsal root ganglion caused by diabetic patients with lumbar disc herniation, and has good prospects for clinical translation.

The application discloses Malania oleifera polysaccharide as well as a preparation method and application thereof. Experimental research proves that the Malania oleifera polysaccharide can promote macrophages to polarize into M2 phenotype, reduce the expression of proinflammatory factors, increase the expression of anti-inflammatory factors, promote epithelialization, collagen deposition and accelerate angiogenesis on a wound surface, has a significant healing-promoting effect on the wound surface, can be prepared into various clinical application dosage forms such as gels and dressings, has excellent biocompatibility and high safety, is suitable for a wide range of application scenarios, can be used for repairing and intervention of various acute and chronic wounds, has important clinical value and market prospect, and provides a safe and efficient new option for clinical wound treatment.

The application belongs to the technical field of biological medicine, and discloses a nano regulator for treating cerebral hemorrhage, a preparation method and application thereof. First, a DNA nanoflower containing a hybridization site is prepared based on RCA technology, and is hybridized with a T structure containing a target transferrin receptor, so that the obtained carrier has the ability to cross the blood-brain barrier and gather at the damage site. Then, the nano regulator TNF@Gin is obtained by loading ginkgo flavones through non-covalent interaction. The obtained nano regulator can promote the polarization of microglial cells to the anti-inflammatory M2 phenotype, thereby reducing the level of pro-inflammatory factors and relieving excessive inflammatory response. In addition, the nano regulator can effectively clear ROS and Nrf2 / GPX4 signal pathway, and inhibit the ferroptosis of hippocampal neuron cells. The nano regulator shows high and safe treatment results, and provides a new strategy for treating cerebral hemorrhage.